Lessons about Botulinum Toxin A Therapy from Cervical Dystonia Patients Drawing the Course of Disease: A Pilot Study.

Publisher: MDPI Country of Publication: Switzerland NLM ID: 101530765 Publication Model: Electronic Cited Medium: Internet ISSN: 2072-6651 (Electronic) Linking ISSN: 20726651 NLM ISO Abbreviation: Toxins (Basel) Subsets: MEDLINE

Original Publication: Basel : MDPI

Botulinum Toxins, Type A* ; Torticollis*/diagnosis ; Torticollis*/drug therapy ; Neuromuscular Agents*; Humans ; Pilot Projects ; Injections ; Treatment Outcome

Aim of the Study: To compare the course of severity of cervical dystonia (CD) before and after long-term botulinum toxin (BoNT) therapy to detect indicators for a good or poor clinical outcome.
Patients and Methods: A total of 74 outpatients with idiopathic CD who were continuously treated with BoNT and who had received at least three injections were consecutively recruited. Patients had to draw the course of severity of CD from the onset of symptoms until the onset of BoNT therapy (CoDB graph), and from the onset of BoNT therapy until the day of recruitment (CoDA graph) when they received their last BoNT injection. Mean duration of treatment was 9.6 years. Three main types of CoDB and four main types of CoDA graphs could be distinguished. The demographic and treatment-related data of the patients were extracted from the patients' charts.
Results: The best outcome was observed in those patients who had experienced a clear, rapid response in the beginning. These patients had been treated with the lowest doses and with a low number of BoNT preparation switches. The worst outcome was observed in those 17 patients who had drawn a good initial improvement, followed by a secondary worsening. These secondary nonresponders had been treated with the highest initial and actual doses and with frequent BoNT preparation switches. A total of 12 patients were primary nonresponders and did not experience any improvement at all. No relation between the CoDB and CoDA graphs could be detected. Primary and secondary nonresponses were observed for all three CoDB types. The use of initial high doses as a relevant risk factor for the later development of a secondary nonresponse was confirmed.
Conclusions: Patients' drawings of their course of disease severity helps to easily detect "difficult to treat" primary and secondary nonresponders to BoNT on the one hand, but also to detect "golden responders" on the other hand.

Toxins (Basel). 2020 Jan 23;12(2):. (PMID: 31979241)
Autoimmunity. 2011 May;44(3):167-76. (PMID: 20843162)
Clin Anat. 2020 Mar;33(2):192-198. (PMID: 31301235)
Toxins (Basel). 2020 Dec 31;13(1):. (PMID: 33396548)
Neurology. 2016 May 10;86(19):1818-26. (PMID: 27164716)
J Pain. 2012 Aug;13(8):784-9. (PMID: 22795247)
Front Neurol. 2017 Feb 24;8:35. (PMID: 28286494)
Eur J Neurol. 2005 Mar;12(3):163-70. (PMID: 15693803)
Parkinsonism Relat Disord. 2018 Dec;57:63-67. (PMID: 30150129)
J Neurol. 2023 Feb;270(2):788-796. (PMID: 36195775)
Neurology. 2005 Jun 14;64(11):1949-51. (PMID: 15955951)
Mov Disord. 2007 Apr 15;22(5):685-9. (PMID: 17274034)
Neurology. 1998 Nov;51(5):1494-6. (PMID: 9818895)
Clin Anat. 2021 Sep;34(6):822-828. (PMID: 32996645)
J Neural Transm (Vienna). 2018 Oct;125(10):1481-1486. (PMID: 30066275)
Pain. 2009 Sep;145(1-2):82-5. (PMID: 19523767)
Lancet. 1971 Jul 17;2(7716):149-50. (PMID: 4104474)
Immunol Invest. 2018 Jan;47(1):18-39. (PMID: 28891721)
J Neurol. 2011 Aug;258(8):1469-76. (PMID: 21365458)
Mov Disord. 1993 Oct;8(4):479-83. (PMID: 8232357)
J Neurol. 2016 Jun;263(6):1188-94. (PMID: 27113604)
J Neurol. 2003 Aug;250(8):967-9. (PMID: 12928917)
J Neural Transm (Vienna). 2014 May;121(5):513-9. (PMID: 24311063)
Lancet Neurol. 2014 Sep;13(9):875-84. (PMID: 25127231)
Mov Disord. 2003 Mar;18(3):303-312. (PMID: 12621634)
Toxins (Basel). 2022 Jan 06;14(1):. (PMID: 35051021)
Eur J Neurol. 2005 Dec;12(12):947-55. (PMID: 16324088)
BMJ Open. 2012 Aug 04;2(4):. (PMID: 22864418)
J Neural Transm (Vienna). 2020 Jan;127(1):45-50. (PMID: 31828512)
J Neurol Neurosurg Psychiatry. 2001 Aug;71(2):193-9. (PMID: 11459891)
J Neurol. 2021 Jan;268(1):206-213. (PMID: 32761340)
J Neurol Neurosurg Psychiatry. 2004 May;75(5):749-53. (PMID: 15090572)
Toxicon. 2018 Jun 1;147:89-95. (PMID: 28888929)
Lancet. 1986 Aug 2;2(8501):245-7. (PMID: 2874278)
Neurology. 2020 May 19;94(20):e2109-e2120. (PMID: 32332130)
BMJ Open. 2013 Apr 18;3(4):. (PMID: 23604344)
J Med Econ. 2012;15(3):419-23. (PMID: 22208596)
Clin Neuropharmacol. 2009 Jul-Aug;32(4):213-8. (PMID: 19620852)
Mov Disord. 2013 Jun 15;28(7):863-73. (PMID: 23649720)
Mov Disord. 2004 Mar;19 Suppl 8:S92-S100. (PMID: 15027060)
Mov Disord. 2012 Dec;27(14):1789-96. (PMID: 23114997)
Toxins (Basel). 2019 Aug 26;11(9):. (PMID: 31454941)
Neurology. 1999 Nov 10;53(8):1871-3. (PMID: 10563645)
Eur J Neurol. 2001 Nov;8 Suppl 5:21-9. (PMID: 11851731)
Neurotox Res. 2016 Jan;29(1):105-17. (PMID: 26467676)

Keywords: CoD graphs; botulinum toxin therapy; cervical dystonia; course of disease (CoD); long-term treatment; primary treatment failure; secondary treatment failure

EC 3.4.24.69 (Botulinum Toxins, Type A)
0 (Neuromuscular Agents)

Date Created: 20230728 Date Completed: 20230731 Latest Revision: 20230901

20230901

PMC10467134

10.3390/toxins15070431

37505701